Actuate Therapeutics, Inc. (ACTU)
| Market Cap | 146.56M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -25.31M |
| Shares Out | 19.62M |
| EPS (ttm) | -1.97 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 507,392 |
| Open | 8.04 |
| Previous Close | 7.49 |
| Day's Range | 7.27 - 8.90 |
| 52-Week Range | 5.51 - 11.99 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 20.00 (+167.74%) |
| Earnings Date | May 15, 2025 |
About ACTU
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company’s lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as metastatic melanoma and colorectal cancer. The company was formerly known as Ap... [Read more]
Analyst Forecast
According to one analyst, the rating for ACTU stock is "Strong Buy" and the 12-month stock price forecast is $20.0.
News
Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO
Phase 2 highlights robust biomarker identification and survival correlations in first-line metastatic pancreatic cancer (mPDAC) treated with elraglusib Phase 2 highlights robust biomarker identificati...
Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
CHICAGO and FORT WORTH, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developin...
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer
CHICAGO and FORT WORTH, Texas, May 31, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
CHICAGO and FORT WORTH, Texas, May 22, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
- Oral presentation at ASCO to highlight topline Phase 2 data of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line treatment of metastatic pancreatic ductal adenocarcinoma ...
Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025
CHICAGO and FORT WORTH, Texas, April 17, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on develop...
Actuate Therapeutics to Participate in Upcoming Investor Conferences in February
CHICAGO and FORT WORTH, Texas, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developin...
Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer
CHICAGO and FORT WORTH, Texas, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developin...
Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development
CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developi...
Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma
CHICAGO and FORT WORTH, Texas, Sept. 09, 2024 (GLOBE NEWSWIRE) -- – Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on develo...
Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference
CHICAGO and FORT WORTH, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on develop...
U.S. IPO Weekly Recap: WeRide Reschedules While 6 New Filers Join The Pipeline
This week was another slow week for pricings, with two companies making their public debut, along with three SPACs. On the filing side, offshore-focused drilling equipment and aftermarket service prov...
Actuate Therapeutics Announces Closing of Initial Public Offering
CHICAGO and FORT WORTH, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Nasdaq: ACTU) (the “Company”), a clinical stage biopharmaceutical company focused on developing therapies f...
Actuate Therapeutics Announces Pricing of Initial Public Offering
CHICAGO and FORT WORTH, Texas, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Nasdaq: ACTU) (the “Company”), a clinical stage biopharmaceutical company focused on developing therapies f...
U.S. IPO Weekly Recap: August Kicks Off With One Small Pricing
U.S. IPO Weekly Recap: August Kicks Off With One Small Pricing
U.S. IPO Weekly Recap: Insurance And Healthcare Lead A 4 IPO Week
A handful of IPOs priced this past week, led by three sizable names. One large issuer joined both the pipeline and the calendar - Chile-based LATAM Airlines Group. Six IPOs are scheduled to list in th...
Actuate Therapeutics Seeks IPO For Promising Pancreatic Cancer Drugs
Actuate Therapeutics, Inc. has filed for a $50 million IPO to raise funds for its treatments for pancreatic cancer and other cancer conditions. The global market for pancreatic cancer treatment is for...
Actuate Therapeutics Files Registration Statement for Initial Public Offering
Actuate Therapeutics, Inc. announced today that it has filed a registration...
Cancer biotech Actuate Therapeutics files for a $50 million IPO
Actuate Therapeutics, a Phase 2 biotech developing in-licensed inhibitor therapies for difficult to treat cancers, filed on Friday with the SEC to raise up to $50 million in an initial public offering...
Actuate Therapeutics IPO Registration Document (S-1)
Actuate Therapeutics has filed to go public with an IPO on the NASDAQ.